Chemotherapy after surgery for locally recurrent nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of two chemotherapy drugs (called TC) given after surgery to remove a nasopharyngeal cancer that has come back locally. The goal is to see if this treatment helps prevent the cancer from returning again and is safe for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a prior diagnosis of nasopharyngeal cancer that has come back in the same area.
- The cancer in the nasal area and neck lymph nodes can be removed with surgery.
- At least 6 months have passed since your last radiation treatment.
- You are between 18 and 70 years old and are generally in good health (able to care for yourself).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You agree to use birth control during the study and for 6 months after, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs and radiation for advanced nasopharyngeal cancer. It aims to improve outcomes by adding a type of immunotherapy and an omega-3 supplement to standard treatment.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
This trial tests a combination of chemotherapy and immunotherapy (pembrolizumab) given before and after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this approach can control the cancer and improve outcomes for patients who can't have standard re-treatment.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
This trial tests giving chemotherapy before and after surgery for people whose nasal cancer has come back. The goal is to see if this approach helps remove the cancer more effectively and prevents it from returning again.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.